BR9711982A - Forma de ingrediente ativo e processos para produzir a mesma - Google Patents

Forma de ingrediente ativo e processos para produzir a mesma

Info

Publication number
BR9711982A
BR9711982A BR9711982A BR9711982A BR9711982A BR 9711982 A BR9711982 A BR 9711982A BR 9711982 A BR9711982 A BR 9711982A BR 9711982 A BR9711982 A BR 9711982A BR 9711982 A BR9711982 A BR 9711982A
Authority
BR
Brazil
Prior art keywords
active ingredient
pct
processes
produce
same
Prior art date
Application number
BR9711982A
Other languages
English (en)
Inventor
Joerg Breitenbach
Horst Baumgartl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR9711982A publication Critical patent/BR9711982A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/04—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent
    • C08J9/12—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent
    • C08J9/122—Hydrogen, oxygen, CO2, nitrogen or noble gases
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2339/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Derivatives of such polymers
    • C08J2339/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
    • C08J2339/06—Homopolymers or copolymers of N-vinyl-pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
BR9711982A 1996-09-03 1997-08-21 Forma de ingrediente ativo e processos para produzir a mesma BR9711982A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19635676A DE19635676A1 (de) 1996-09-03 1996-09-03 Feste geschäumte Wirkstoffzubereitungen
PCT/EP1997/004550 WO1998009616A1 (de) 1996-09-03 1997-08-21 Feste geschäumte wirkstoffzubereitungen

Publications (1)

Publication Number Publication Date
BR9711982A true BR9711982A (pt) 1999-08-24

Family

ID=7804471

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711982A BR9711982A (pt) 1996-09-03 1997-08-21 Forma de ingrediente ativo e processos para produzir a mesma

Country Status (22)

Country Link
US (1) US6150424A (pt)
EP (1) EP0932393B1 (pt)
JP (1) JP2000517327A (pt)
CN (1) CN1124129C (pt)
AT (1) ATE215362T1 (pt)
AU (1) AU740856B2 (pt)
BG (1) BG103214A (pt)
BR (1) BR9711982A (pt)
CA (1) CA2264588C (pt)
CZ (1) CZ67699A3 (pt)
DE (2) DE19635676A1 (pt)
DK (1) DK0932393T3 (pt)
ES (1) ES2175469T3 (pt)
HR (1) HRP970472A2 (pt)
HU (1) HUP9904101A3 (pt)
IL (1) IL128439A (pt)
NO (1) NO991011L (pt)
PT (1) PT932393E (pt)
RU (1) RU2200004C2 (pt)
TR (1) TR199900447T2 (pt)
WO (1) WO1998009616A1 (pt)
ZA (1) ZA977861B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19733505A1 (de) * 1997-08-01 1999-02-04 Knoll Ag Schnell wirksames Analgeticum
DE19900457A1 (de) * 1999-01-08 2000-07-13 Basf Ag Verfahren zur Herstellung von festen Dosierungsformen
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
DE10032456A1 (de) 2000-07-04 2002-01-31 Lohmann Therapie Syst Lts Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030165564A1 (en) * 2001-10-29 2003-09-04 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US20030118652A1 (en) * 2001-11-15 2003-06-26 John Kelly Methods and compositions for use of (S)-bisoprolol
US20030091633A1 (en) * 2001-11-15 2003-05-15 John Kelly Methods and compositions for use of (S)-bisoprolol
AU2003206382B2 (en) * 2002-01-03 2008-01-24 Smithkline Beecham Corporation Novel pharmaceutical dosage forms and method for producing same
DE10207394B4 (de) * 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
US20030235613A1 (en) * 2002-06-19 2003-12-25 Cts Chemical Industries Ltd. Popping oral administration form
DE10227607A1 (de) * 2002-06-20 2004-01-08 Boxler Gmbh & Co. Kg Paneel-Verbindung
CA2515369C (en) * 2003-02-06 2015-03-31 Cerus Corporation Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
AU2004224425B2 (en) * 2003-02-06 2010-06-24 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7695725B2 (en) * 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005023215A2 (en) * 2003-09-10 2005-03-17 Janssen Pharmaceutica N.V. Particles shaped as platelets
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
FR2886938B1 (fr) * 2005-06-10 2008-04-18 Armines Ass Loi De 1901 Procede d'extrusion permettant de fabriquer des dispersions solides de principes actifs pharmaceutiques dans une matrice polymere
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
BRPI1010511A2 (pt) * 2009-04-09 2019-04-09 Alkermes Pharma Ireland Limited composição, e, métodos para tratar um paciente que sofre de esquizofrenia, e para reduzir o risco de comportamento suicida recorrente em um paciente com esquizofrenia ou desordem esquizoafetiva
US20110172210A1 (en) * 2010-01-13 2011-07-14 Azur Pharma Limited Method for titrating clozapine
JP2013523092A (ja) 2010-03-26 2013-06-17 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 非喫煙用タバコ製品の消費中の感覚刺激の抑制
US8952038B2 (en) 2010-03-26 2015-02-10 Philip Morris Usa Inc. Inhibition of undesired sensory effects by the compound camphor
WO2011144731A1 (de) * 2010-05-21 2011-11-24 Basf Se Nanoporöse geschäumte wirkstoffhaltige zubereitungen auf basis von pharmazeutisch akzeptablen thermoplastisch verarbeitbaren polymeren
EP2571490A2 (en) * 2010-05-21 2013-03-27 President and Fellows of Harvard College Foam or particles for applications such as drug delivery
US8636929B2 (en) 2010-05-21 2014-01-28 Basf Se Nanoporous foamed active compound-containing preparations based on pharmaceutically acceptable thermoplastically workable polymers
WO2011144727A1 (de) * 2010-05-21 2011-11-24 Basf Se ZUBEREITUNGEN BIOLOGISCH AKTIVER SUBSTANZEN MIT VERGRÖßERTER OBERFLÄCHE AUF BASIS VON AMPHIPHILEN COPOLYMEREN
EP2463327A3 (de) * 2010-12-10 2015-06-03 Basf Se Verfahren zur herstellung von granulaten, enthaltend mindestens eine wasserlösliche komponente
MX341035B (es) 2011-03-01 2016-08-03 Procter & Gamble Sustrato solido desintegrable poroso para aplicaciones para el cuidado personal.
CN106255511A (zh) * 2014-04-30 2016-12-21 A·H·布莱斯 熔融加工聚合物细胞状剂型
WO2019069108A1 (en) * 2017-10-04 2019-04-11 Debreceni Egyetem SOLID GALENIC FORM, MOLDED, GASTRIC RETENTION AND EXTENDED RELEASE AND METHOD OF PREPARING THE SAME
DE102020110089A1 (de) * 2020-04-09 2021-10-14 Karl-Franzens-Universität Graz Verfahren zum Herstellen eines porösen Wirkstoffträgers mittels Heißschmelzextrusion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
IT1247529B (it) * 1991-04-24 1994-12-17 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale
JP2966735B2 (ja) * 1994-07-29 1999-10-25 積水化成品工業株式会社 熱可塑性樹脂押出機

Also Published As

Publication number Publication date
ZA977861B (en) 1999-03-02
JP2000517327A (ja) 2000-12-26
TR199900447T2 (xx) 1999-05-21
CA2264588C (en) 2005-10-18
IL128439A (en) 2003-02-12
RU2200004C2 (ru) 2003-03-10
CA2264588A1 (en) 1998-03-12
DE59706898D1 (de) 2002-05-08
PT932393E (pt) 2002-09-30
CN1124129C (zh) 2003-10-15
DK0932393T3 (da) 2002-07-01
ATE215362T1 (de) 2002-04-15
IL128439A0 (en) 2000-01-31
EP0932393A1 (de) 1999-08-04
NO991011L (no) 1999-03-03
US6150424A (en) 2000-11-21
BG103214A (en) 1999-09-30
CN1237103A (zh) 1999-12-01
HUP9904101A2 (hu) 2000-04-28
HRP970472A2 (en) 1998-08-31
WO1998009616A1 (de) 1998-03-12
CZ67699A3 (cs) 1999-05-12
AU4617797A (en) 1998-03-26
ES2175469T3 (es) 2002-11-16
HUP9904101A3 (en) 2001-11-28
DE19635676A1 (de) 1998-03-05
AU740856B2 (en) 2001-11-15
NO991011D0 (no) 1999-03-02
EP0932393B1 (de) 2002-04-03

Similar Documents

Publication Publication Date Title
BR9711982A (pt) Forma de ingrediente ativo e processos para produzir a mesma
BR0308629A (pt) Sistema de comunicação, nó de comunicação para uso no mesmo, e, método de comunicação
DE60129849D1 (de) Bioadhäsiver schaumstoffilm mit hinhaltender wirkstoffreigabe
RS50031B (sr) Triciklični inhibitori poli(adp-riboza)polimeraza
MX9802383A (es) Derivados de pirimidina como antagonistas del receptor 5ht26.
ES2191286T3 (es) Moleculas pequeñas, utiles en el tratamiento de enfermedades inflamatorias.
FI943168A0 (fi) Opioidiformulaatioita, joissa on pitkitetty säädelty vapautuminen
HK1044349B (zh) 含有1，1，1，3，3-五氟丁烷的組合物及此種組合物的用途
MX9205032A (es) 1,2-dihidro-2-oxo-piridinas y procedimiento para su preparacion.
PT885098E (pt) Agente de proteccao da madeira para trabalhos de manutencao
PT896534E (pt) Formulacoes para injeccao de avermectinas e milbemicinas a base de oleo de ricino
DK0937074T3 (da) Benzonaphthyridiner som bronkiale terapeutiske midler
ATE212971T1 (de) Schmelzbare stabilisatorkombination
ATE265997T1 (de) Substituierte tetrahydronaphthalin- und dihydronaphthalin-derivate mit einer retinoiden und/oder retinoid antagonist-ähnlichen biologischen aktivität
AR016981A2 (es) Polipeptidos sinteticos
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
NO972502D0 (no) 1,4-Diaryl-2-fluor-2-butan-insekticid- og akaricid-midler
RS49520B (sr) Antimikrobno aktivne smeše
BR9711273A (pt) 1,2,3,4- Tetraidro-2-dibenzofuranaminas substituidas e 2- aminociclohepta b benzofuranos
ZA975638B (en) New synthetic catechol derivatives, methods of producing them and their use.
EP0919223A4 (en) SKIN AGING PROTECTIVE AGENT
HRP20000703B1 (en) Stabile compositions levosimendan and alginic acid
ES2131482A1 (es) Formulacion acuosa de bambuterol.
DE69818988D1 (de) 9,10-diazatryclo[4.2.11 2,5]decan- und 9,10-diazatricyclo[3.3.1.1 2,6]decanderive mit analgetischer wirkung
GB0119121D0 (en) Improvements in and relating to computer systems

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]